肛门癌的淋巴结分期转移与预后:系统评价、荟萃回归和模拟研究。

Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study.

机构信息

Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester, UK.

Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

出版信息

Lancet Oncol. 2017 Oct;18(10):1348-1359. doi: 10.1016/S1470-2045(17)30456-4. Epub 2017 Aug 9.

Abstract

BACKGROUND

In patients with squamous cell carcinoma of the anus (SCCA), lymph node positivity (LNP) indicates poor prognosis for survival and is central to radiotherapy planning. Over the past three decades, LNP proportion has increased, mainly reflecting enhanced detection with newer imaging modalities; a process known as nodal stage migration. If accompanied by constant T stage distributions, prognosis for both lymph node-positive and lymph node-negative groups may improve without any increase in overall survival for individual patients; a paradox termed the Will Rogers phenomenon. Here, we aim to systematically evaluate the impact of nodal stage migration on survival in SCCA and address a novel hypothesis that this phenomenon results in reduced prognostic discrimination.

METHODS

We did a systematic review and meta-regression to quantify changes in LNP over time and the impact of this change on survival and prognostic discrimination. We searched MEDLINE, Embase, and the Cochrane Library to identify randomised trials and observational studies in patients with SCCA published between Jan 1, 1970, and Oct 11, 2016. Studies were eligible if patients received chemoradiotherapy or radiotherapy as the main treatment, reported LNP proportions (all studies), and reported overall survival (not necessarily present in all studies). We excluded studies with fewer than 50 patients. We extracted study-level data with a standardised, piloted form. The primary outcome measure was 5-year overall survival. To investigate scenarios in which reduced prognostic discrimination might occur, we simulated varying true LNP proportions and true overall survival, and compared these with expected observed outcomes for varying levels of misclassification of true nodal state.

FINDINGS

We identified 62 studies reporting LNP proportions, which included 10 569 patients. From these, we included 45 studies (6302 patients) with whole cohort 5-year overall survival, 11 studies with 5-year survival stratified by nodal status, and 20 studies with hazard ratios in our analyses of temporal changes. In 62 studies, the LNP proportions increased from a mean estimate of 15·3% (95% CI 10·5-20·1) in 1980 to 37·1% (34·0-41·3) in 2012 (p<0·0001). In 11 studies with prognostic data, increasing LNP was associated with improved overall survival in both lymph node-positive and lymph node-negative categories, whereas the proportions with combined tumour stage T3 and T4 remained constant. In 20 studies, across a range of LNP proportions from 15% to 40%, the hazard ratios for overall survival of lymph node-positive versus lymph node-negative patients decreased significantly from 2·5 (95% CI 1·8-3·3) at 15% LNP to 1·3 (1·2-1·9; p=0·014) at 40% LNP. The simulated scenarios reproduced this effect if the true LNP proportions were 20% or 25%, but not if the true LNP proportions were 30% or greater.

INTERPRETATION

We describe a consequence of staging misclassification in anal cancer that we have termed reduced prognostic discrimination. We used this new observation to infer that the LNP proportions of more than 30% seen in modern clinical series (11 out of 15 studies with a median year since 2007) are higher than the true LNP proportion. The introduction of new staging technologies in oncology might misclassify true disease stage, spuriously informing disease management and ultimately increasing the risk of overtreatment.

FUNDING

Bowel Disease Research Foundation.

摘要

背景

在肛门鳞状细胞癌(SCCA)患者中,淋巴结阳性(LNP)预示着生存预后不良,是放疗计划的核心。在过去的三十年中,LNP 比例有所增加,主要反映了新型成像方式的检测能力增强;这一过程被称为淋巴结分期迁移。如果伴随着 T 分期的分布保持不变,那么无论是淋巴结阳性组还是淋巴结阴性组,其预后都可能改善,而单个患者的总体生存率并没有增加;这种被称为威尔·罗杰斯现象的悖论。在这里,我们旨在系统评估淋巴结分期迁移对 SCCA 生存的影响,并提出一个新的假设,即这种现象导致预后区分度降低。

方法

我们进行了系统评价和荟萃回归分析,以量化 LNP 随时间的变化以及这种变化对生存和预后区分的影响。我们检索了 MEDLINE、Embase 和 Cochrane 图书馆,以确定 1970 年 1 月 1 日至 2016 年 10 月 11 日发表的 SCCA 患者的随机试验和观察性研究。如果患者接受了放化疗或放疗作为主要治疗方法,报告了 LNP 比例(所有研究),并报告了总生存率(并非所有研究都有),则研究符合入选标准。我们排除了患者少于 50 人的研究。我们使用标准化的、试验性表格提取了研究级别的数据。主要观察指标是 5 年总生存率。为了研究预后区分度降低可能发生的情况,我们模拟了不同的真实 LNP 比例和真实总生存率,并将这些结果与不同程度的真实淋巴结状态分类错误的预期观察结果进行了比较。

结果

我们确定了 62 项报告 LNP 比例的研究,其中包括 10569 名患者。在这些研究中,我们纳入了 45 项(6302 名患者)的整体队列 5 年总生存率、11 项按淋巴结状态分层的 5 年生存率以及 20 项危险比的研究,以分析时间变化。在 62 项研究中,LNP 比例从 1980 年的平均 15.3%(95%CI 10.5-20.1)增加到 2012 年的 37.1%(34.0-41.3)(p<0.0001)。在 11 项具有预后数据的研究中,LNP 的增加与淋巴结阳性和淋巴结阴性患者的总生存率提高相关,而 T3 和 T4 联合肿瘤分期的比例保持不变。在 20 项研究中,在 LNP 比例为 15%至 40%的范围内,淋巴结阳性与淋巴结阴性患者的总生存率的危险比从 LNP 比例为 15%时的 2.5(95%CI 1.8-3.3)显著下降至 LNP 比例为 40%时的 1.3(1.2-1.9;p=0.014)。如果真实的 LNP 比例为 20%或 25%,模拟情景会产生这种效果,但如果真实的 LNP 比例为 30%或更高,则不会产生这种效果。

解释

我们描述了在肛门癌分期中出现的一种后果,我们称之为预后区分度降低。我们利用这一新的观察结果推断,在现代临床系列(自 2007 年以来中位数为 11 项研究)中看到的超过 30%的 LNP 比例高于真实的 LNP 比例。肿瘤学中新分期技术的引入可能会错误分类真正的疾病分期,从而错误地告知疾病管理,并最终增加过度治疗的风险。

资助

肠道疾病研究基金会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索